Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide

Prostate

Volumn 71, Issue 10, 2011, Pages 1064-1073

  Gouazé Andersson, Valérie ^a   Flowers, Margaret ^a   Karimi, Ramin ^a   Fabriás, Gemma ^b   Delgado, Antonio ^b,c   Casas, Josefina ^b   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

cancer; ceramidase; ceramide; chemotherapy; synthetic retinoids

Indexed keywords

ACID CERAMIDASE; ALPHA TOCOPHEROL; AMIDE; CASPASE 3; CASPASE 7; CERAMIDE; DM 102; FENRETINIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIZATION;

AMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CERAMIDASES; DRUG INTERACTIONS; ETHANOLAMINES; FATTY ACIDS, UNSATURATED; FENRETINIDE; HUMANS; REACTIVE OXYGEN SPECIES; VITAMIN E;

EID: 79955829728     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21321     Document Type: Article

References (46)

1. Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A,. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 2005; 41 (6): 908-921. (Pubitemid 40461691)
2. Peschel RE, Colberg JW,. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4 (4): 233-241. (Pubitemid 36503321)
3. Hanks GE, Hanlon AL, Epstein B, Horwitz EM,. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 2002; 54 (2): 427-435. (Pubitemid 35286808)
4. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC,. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268 (5212): 884-886.
5. Thompson TC,. Growth factors and oncogenes in prostate cancer. Cancer Cells 1990; 2 (11): 345-354. (Pubitemid 20384141)
6. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA,. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54 (14): 3929-3933. (Pubitemid 24241218)
7. Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W,. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 2000; 29 (2): 137-146.
8. Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S, Dong JY, McKillop J, Norris K, Obeid L, Rubinchik S, Tavassoli M, Tomlinson S, Voelkel-Johnson C, Liu X,. Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 2006; 13 (12): 1045-1051. (Pubitemid 44760102)
9. Sugita M, Dulaney JT, Moser HW,. Ceramidase deficiency in Farber's disease (lipogranulomatosis). Science 1972; 178 (65): 1100-1102.
10. Ferlinz K, Kopal G, Bernardo K, Linke T, Bar J, Breiden B, Neumann U, Lang F, Schuchman EH, Sandhoff K,. Human acid ceramidase: processing, glycosylation, and lysosomal targeting. J Biol Chem 2001; 276 (38): 35352-35360.
11. Gatt S,. Enzymic hydrolysis and synthesis of ceramides. J Biol Chem 1963; 238: 3131-3133.
12. Hannun YA, Obeid LM,. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995; 20 (2): 73-77.
13. Geilen CC, Wieder T, Orfanos CE,. Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis. Arch Dermatol Res 1997; 289 (10): 559-566. (Pubitemid 27477647)
14. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, Spiegel S,. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381 (6585). 800-803. (Pubitemid 26243122)
15. Abe A, Radin NS, Shayman JA, Wotring LL, Zipkin RE, Sivakumar R, Ruggieri JM, Carson KG, Ganem B,. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 1995; 36 (3): 611-621.
16. Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, Turner LS, Cheng J, Bielawska A, Bielawski J, Keane TE, Obeid LM, Hannun YA, Norris JS, Liu X,. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007; 6 (9): 1455-1460. (Pubitemid 351590358)
17. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, Clavien PA,. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61 (3): 1233-1240. (Pubitemid 32174448)
18. Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N, Beckham TH, Saad A, Bielawska A, Bielawski J, Hannun YA, Keane TE, Taha MI, Hammouda HM, Norris JS, Liu X,. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 2009; 17 (3): 430-438.
19. Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, Eberle J, Hannun YA, Orfanos CE, Geilen CC,. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 2002; 516 (1-3): 47-52. (Pubitemid 34311931)
20. Eto M, Bennouna J, Hunter OC, Lotze MT, Amoscato AA,. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol 2006; 13 (2): 148-156. (Pubitemid 43362971)
21. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AM, Bielawska A, Smyth MJ,. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004; 58 (4): 382-393. (Pubitemid 38295032)
22. Castillo SS, Teegarden D,. Ceramide conversion to sphingosine-1-phosphate is essential for survival in C3H10T1/2 cells. J Nutr 2001; 131 (11): 2826-2830. (Pubitemid 33063109)
23. Bedia C, Canals D, Matabosch X, Harrak Y, Casas J, Llebaria A, Delgado A, Fabrias G,. Cytotoxicity and acid ceramidase inhibitory activity of 2-substituted aminoethanol amides. Chem Phys Lipids 2008; 156 (1-2): 33-40.
24. Bonanni B, Lazzeroni M,. Retinoids and breast cancer prevention. Recent Results Cancer Res 2009; 181: 77-82.
25. Colombo N, Formelli F, Cantu MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A,. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006; 15 (10): 1914-1919. (Pubitemid 44664268)
26. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G,. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006; 17 (7): 1065-1071. (Pubitemid 43985241)
27. Pienta KJ, Nguyen NM, Lehr JE,. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993; 53 (2): 224-226. (Pubitemid 23031826)
28. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC,. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 2000; 18 (5): 429-438. (Pubitemid 32588624)
29. Shen JC, Wang TT, Chang S, Hursting SD,. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl) retinamide on prostate cancer cell growth and apoptosis. Mol Carcinog 1999; 24 (3): 160-168. (Pubitemid 29169856)
30. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR,. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer 2009; 7 (1): 43-50.
31. Bedia C, Casas J, Garcia V, Levade T, Fabrias G,. Synthesis of a novel ceramide analogue and its use in a high-throughput fluorogenic assay for ceramidases. Chembiochem 2007; 8 (6): 642-648. (Pubitemid 47194856)
32. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC,. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996; 271 (32): 19530-19536. (Pubitemid 26271630)
33. Liu YY, Han TY, Giuliano AE, Cabot MC,. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 1999; 274 (2): 1140-1146.
34. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
35. Wang H, Charles AG, Frankel AJ, Cabot MC,. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Urology 2003; 61 (5): 1047-1052. (Pubitemid 36547768)
36. Ogretmen B, Hannun YA,. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4 (8): 604-616. (Pubitemid 39025055)
37. Ozben T,. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007; 96 (9): 2181-2196. (Pubitemid 47477879)
38. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP,. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 91 (13): 1138-1146. (Pubitemid 29330552)
39. Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F, Sonnino S,. Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 2003; 278 (8): 5574-5583. (Pubitemid 36800799)
40. Senchenkov A, Litvak DA, Cabot MC,. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J Natl Cancer Inst 2001; 93 (5): 347-357. (Pubitemid 32229379)
41. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC,. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 2000; 275 (10): 7138-7143. (Pubitemid 30146262)
42. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC,. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 2005; 65 (9): 3861-3867. (Pubitemid 40616367)
43. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC,. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997; 272 (3): 1682-1687. (Pubitemid 27043253)
44. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y,. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 2006; 342 (4): 1284-1290.
45. Olivera A, Spiegel S,. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993; 365 (6446): 557-560. (Pubitemid 23317779)
46. Illuzzi G, Bernacchioni C, Aureli M, Prioni S, Frera G, Donati C, Valsecchi M, Chigorno V, Bruni P, Sonnino S, Prinetti A,. Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl) retinamide in human ovarian cancer cells. J Biol Chem 2010; 285 (24): 18594-18602.